N4 Pharma Plc

AIM:N4P Stock Report

Market Cap: UK£2.6m

N4 Pharma Valuation

Is N4P undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of N4P when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate N4P's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate N4P's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for N4P?

Key metric: As N4P barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for N4P. This is calculated by dividing N4P's market cap by their current book value.
What is N4P's PB Ratio?
PB Ratio2.1x
BookUK£1.25m
Market CapUK£2.57m

Price to Book Ratio vs Peers

How does N4P's PB Ratio compare to its peers?

The above table shows the PB ratio for N4P vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average17.3x
CEL Celadon Pharmaceuticals
3.9xn/aUK£9.5m
KNB Kanabo Group
1xn/aUK£6.0m
STX Shield Therapeutics
51.7x84.6%UK£22.3m
FUM Futura Medical
12.8x188.3%UK£99.6m
N4P N4 Pharma
2.1xn/aUK£2.6m

Price-To-Book vs Peers: N4P is good value based on its Price-To-Book Ratio (2.1x) compared to the peer average (17.3x).

Price to Book Ratio vs Industry

How does N4P's PB Ratio compare vs other companies in the GB Pharmaceuticals Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
EAH ECO Animal Health Group
0.5x34.2%US$54.43m
OCTP Oxford Cannabinoid Technologies Holdings
0.6x15.1%US$1.60m
NFX Nuformix
0.1xn/aUS$560.44k
No more companies available in this PB range
N4P 2.1xIndustry Avg. 2.3xNo. of Companies3PB03.67.210.814.418+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: N4P is good value based on its Price-To-Book Ratio (2.1x) compared to the European Pharmaceuticals industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is N4P's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

N4P PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate N4P's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Formycon

€848.4m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.50

7D

4.3%

1Y

-21.3%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€63.05

7D

1.3%

1Y

13.6%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$745.13

7D

-2.1%

1Y

-6.5%